European Pharmaceutical Review

NOVEMBER 21, 2024

In June, the US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) rejected 1 Lykos Therapeutics’ psychedelic new drug application (NDA) for midomafetamine (MDMA) capsules used alongside MDMA-assisted therapy to treat post-traumatic stress disorder (PTSD) in adults.

Food and Drug Administration 97

Food and Drug Administration Safety FDA Ethics 97

European Pharmaceutical Review

JULY 21, 2023

A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. Some countries have blocked parallel trade to prevent supplies from depleting.

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Transportation Manufacturing 98

Pharmaceutical Representative Training

JUNE 22, 2024

They must be familiar with the different national authorities; the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulations that govern the pharmaceutical marketing and sales. Ethical Conduct: In pharma sales, ethical conduct and behavior is crucial.

Sales 52

Sales Pharmaceutical Ethics Pharmaceutical Sales 52

PM360

NOVEMBER 21, 2024

Winning a Lifetime Achievement Award after 40+ Years of Leadership Labcorp’s Adam Schechter was presented a Lifetime Achievement Award at the 2024 Trailblazer Awards, which took place at Gotham Hall in New York City, October 1. Adam is an ethical leader who leads his business to serve the needs of patients and advance healthcare globally.

Ethics 59

Ethics Food and Drug Administration Marketing Healthcare 59

PM360

JUNE 24, 2024

This is partly due to the limited market potential for drugs in the space, but also due to the sheer volume of rare diseases: approximately 6,000–8,000 have been identified. The overarching theme: As with rare disease drug development, precision and personalization are key. Food & Drug Administration (FDA).

Marketing 52

Marketing Patients Food and Drug Administration Digital Media 52

Nixon Gwilt Law

APRIL 22, 2024

HHS DSI Presentation (1/18/2024) Specifically, the HTI-1 Final Rule establishes algorithm transparency and risk management requirements and introduces the agency’s “FAVES” principles. Appropriate: Guarantees that DSIs are suitable for the contexts and populations in which they are used, adhering to relevant clinical and ethical standards.

Healthcare 52

Healthcare Healthcare Training Food and Drug Administration 52

Nixon Gwilt Law

APRIL 22, 2024

HHS DSI Presentation (1/18/2024) Specifically, the HTI-1 Final Rule establishes algorithm transparency and risk management requirements and introduces the agency’s “FAVES” principles. Appropriate: Guarantees that DSIs are suitable for the contexts and populations in which they are used, adhering to relevant clinical and ethical standards.

Healthcare 52

Healthcare Healthcare Training Food and Drug Administration 52